Senesco Announces $1.725 Million Equity Financing BRIDGEWATER, N.J. (

Senesco Announces $1.725 Million Equity

BRIDGEWATER, N.J. (October 1, 2013)

- Senesco Technologies, Inc. ("Senesco" or the "Company") (OTCQB: SNTI) announced

today that it has entered into a securities purchase agreement with certain investors to raise $1.725 million in gross proceeds

through the sale of 69,000,000 shares of its common stock. The common stock was priced at $0.025 per share.

The offering is expected

to close on or about October 2, 2013, subject to customary closing conditions. The net proceeds of the financing will be used primarily

for working capital, research and development and general corporate purposes.

"We are very pleased

to have enhanced our financial resources," said Leslie J. Browne, Ph.D., President and CEO of Senesco. "This infusion

of funds will enable the advancement of SNS01-T in the on-going B-cell cancer study in patients with multiple myeloma, mantle cell

lymphoma and diffuse large cell lymphoma."

The shares are being offered

pursuant to a prospectus forming a part of the Company's effective registration statement (File No. 333-189998) filed with

the Securities and Exchange Commission (the "SEC"), which was declared effective by the SEC on September 30, 2013,

a copy of which may be obtained, when available, at the SEC's website at http://www.sec.gov.

This press release does

not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sale of these securities

in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification

under the securities laws of any such state or jurisdiction.

Additional terms of this

offering (including the full terms and conditions of the securities purchase agreement) were disclosed on a Form 8-K filed with

the SEC by Senesco simultaneously with this press release and will also be disclosed in the prospectus filed with the SEC in connection

SNS01-T is a novel approach to cancer therapy

that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large

B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester,

MN, the University of Arkansas for Medical Sciences in Little Rock, the Mary Babb Randolph Cancer Center in Morgantown, WV, the

John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, NJ and the Seattle Cancer Care Alliance in Seattle,

WA. http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1

About Senesco Technologies,

Senesco, a leader in eIF5A technology,

is sponsoring a clinical study to evaluate its lead therapeutic candidate SNS01-T in multiple myeloma, diffuse large B-cell lymphoma

and mantle cell lymphoma. SNS01-T targets B-cell cancers and selectively induces apoptosis by modulating eukaryotic translation

initiation factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis

may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic

diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and biofuels development,

and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated

into its partners' commercialized products.

Forward-Looking Statements

Certain statements included

in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including,

but not limited to: the Company's ability to continue as a going concern; the Company's ability to recruit patients

for its clinical trial; the ability of the Company to consummate additional financings; the development of the Company's

gene technology; the approval of the Company's patent applications; the current uncertainty in the patent landscape surrounding

small inhibitory RNA and the Company's ability to successfully defend its intellectual property or obtain the necessary licenses

at a cost acceptable to the Company, if at all; the successful implementation of the Company's research and development programs

and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products;

the timing and success of the Company's preliminary studies, preclinical research and clinical trials; competition and the

timing of projects and trends in future operating performance, the quotation of the Company's common stock on an over-the-counter

securities market, as well as other factors expressed from time to time in the Company's periodic filings with the Securities

and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's

periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release,

and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.